U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H24FN7O.ClH
Molecular Weight 481.953
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELONSERTIB HYDROCHLORIDE

SMILES

Cl.CC(C)N1C=NN=C1C2=CC=CC(NC(=O)C3=CC(N4C=NC(=C4)C5CC5)=C(C)C=C3F)=N2

InChI

InChIKey=DQKKBHINKKMQHS-UHFFFAOYSA-N
InChI=1S/C24H24FN7O.ClH/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16;/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C24H24FN7O
Molecular Weight 445.4921
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800040265 https://www.ncbi.nlm.nih.gov/pubmed/25531162

Selonsertib, also known as GS-4997, is a small-molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1), which promotes inflammation, apoptosis and fibrosis in settings of increased oxidative stress associated with NASH pathogenesis. GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. GS-4997 is currently being evaluated in an ongoing Phase 2 study in patients with NASH and moderate to severe liver fibrosis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease.
2015
A Quantitative Framework to Evaluate Proarrhythmic Risk in a First-in-Human Study to Support Waiver of a Thorough QT Study.
2015 Dec
Patents

Sample Use Guides

Selonsertib tablets 2 mg, 6 mg, 18 mg for 48 weeks, administered orally once daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:18:26 GMT 2023
Edited
by admin
on Sat Dec 16 10:18:26 GMT 2023
Record UNII
A24IO3O2HW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELONSERTIB HYDROCHLORIDE
Common Name English
BENZAMIDE, 5-(4-CYCLOPROPYL-1H-IMIDAZOL-1-YL)-2-FLUORO-4-METHYL-N-(6-(4-(1-METHYLETHYL)-4H-1,2,4-TRIAZOL-3-YL)-2-PYRIDINYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
A24IO3O2HW
Created by admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
PRIMARY
SMS_ID
300000013051
Created by admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
PRIMARY
PUBCHEM
71654746
Created by admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
PRIMARY
CAS
1448428-05-4
Created by admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
PRIMARY